GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protara Therapeutics Inc (NAS:TARA) » Definitions » Price-to-Operating-Cash-Flow

TARA (Protara Therapeutics) Price-to-Operating-Cash-Flow : (As of May. 13, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Protara Therapeutics Price-to-Operating-Cash-Flow?

As of today (2025-05-13), Protara Therapeutics's share price is $3.27. Protara Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.99. Hence, Protara Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Protara Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

TARA's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 24.035
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Protara Therapeutics's Cash Flow from Operations per share for the three months ended in Dec. 2024 was $-0.34. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.99.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 17.30% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -10.00% per year.

During the past 7 years, Protara Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 30.30% per year. The lowest was -40.00% per year. And the median was 8.25% per year.


Protara Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Protara Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protara Therapeutics Price-to-Operating-Cash-Flow Chart

Protara Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - - -

Protara Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Protara Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Protara Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protara Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protara Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Protara Therapeutics's Price-to-Operating-Cash-Flow falls into.


;
;

Protara Therapeutics Price-to-Operating-Cash-Flow Calculation

Protara Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=3.27/-1.989
=

Protara Therapeutics's Share Price of today is $3.27.
Protara Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.99.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Protara Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Protara Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Protara Therapeutics Business Description

Traded in Other Exchanges
Address
345 Park Avenue South, 3rd Floor, New York, NY, USA, 10010
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Executives
Jacqueline Zummo officer: Sr. Vice President, Research C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Patrick Fabbio officer: Chief Financial Officer 2 PITNEY COURT, BASKING RIDGE NJ 07920
Jesse Shefferman director, officer: CEO and President C/O ARTARA THERAPEUTICS,INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Hannah Fry officer: VP, Controller 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Luke M Beshar director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Jathin Bandari officer: Chief Medical Officer C/O PROTORA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Jane Huang director C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Martin Sebastian Olivo officer: Chief Medical Officer C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Blaine Davis officer: Chief Financial Officer C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Randall Marshall 10 percent owner C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Barry P Flannelly director ROUTE 141 AND HENRY CLAY ROAD, WILMINGTON DE 19880
Julio Casoy officer: Chief Medical Officer C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Richard S Levy director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014